Time to antidepressant discontinuation: a comparison of controlled-release paroxetine and immediate-release selective serotonin-reuptake inhibitors.
Manag Care Interface
; 16(12): 22-7, 2003 Dec.
Article
em En
| MEDLINE
| ID: mdl-14750459
ABSTRACT
Despite advances in depression therapy, early treatment discontinuation with antidepressants remains high and contributes to poor clinical outcomes. In clinical trials, treatment discontinuation with controlled-release paroxetine was similar to placebo and significantly better than immediate-release paroxetine. To examine whether this benefit noted in clinical trials translated into longer therapy duration in practice settings, survival-analysis models were constructed to compare the time to treatment discontinuation of controlled-release paroxetine with that of immediate-release selective serotonin-reuptake inhibitors (SSRIs). Survival analysis indicated that patients receiving controlled-release paroxetine were 28% less likely to discontinue therapy during a 180-day period when compared with patients receiving immediate-release SSRIs.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Transtornos de Ansiedade
/
Programas de Assistência Gerenciada
/
Inibidores Seletivos de Recaptação de Serotonina
/
Paroxetina
/
Transtorno Depressivo
/
Antidepressivos
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Male
País/Região como assunto:
America do norte
Idioma:
En
Ano de publicação:
2003
Tipo de documento:
Article